Esketamine combined with an SNRI is more effective for treatment-resistant depression (TRD) than when paired with an SSRI. Analysis of over 55,000 patients showed that the SNRI combination ...

Amelia D. has been in an esketamine trial since 2017. Here's what it's like to take ketamine-derived esketamine, the new depression drug.

Esketamine is a more potent form of ketamine, an anesthetic that doctors have used for many years to treat depression. The nasal spray, from Janssen Pharmaceuticals, ...

Nasal esketamine spray is more effective than an extended-release antipsychotic, when both are taken in combination with SSRIs and SNRIs, in treatment-resistant depression, a study found.

“Esketamine is essentially ketamine,” says Dr. Dan Iosifescu, associate professor of psychiatry at NYU Langone Health who specializes in treating people with treatment-resistant depression.

Esketamine nasal spray (Spravato) paired with oral antidepressants remained effective long-term for patients with treatment-resistant depression who responded to the therapy, according to a ...

Esketamine faces similar limitations, and if approved will also be administered in the clinic. This article is reproduced with permission and was first published on October 30, 2018.

Esketamine, administered as a nasal spray, is a cousin of the anesthetic ketamine, which was once a popular recreational drug. Studies have shown ketamine's effectiveness against depression, ...

Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy, with 22. ...

More information: Jennifer Kern Sliwa et al, Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery ...

"Esketamine was studied up to four months, but depression can be a life long illness." Additionally, she says, since the drug has only been tested on a small group of patients, ...

Esketamine became the first FDA-approved psychedelic treatment for a psychiatric disorder. In August of last year, the FDA extended its approval for esketamine to adults with major depressive ...